Product Details
Vemlidy
Tenofovir Alafenamide (Tenofovir Alafenamide Hemifumarate)25 mg
Tablet
DIN/PIN/NPN
02464241
Manufacturer
Gilead Sciences Canada, Inc.
Formulary Listing Date
2026-01-30
Unit Price
19.5537
Amount MOH Pays
19.5537
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
J05AF13
Interchangeable Products
NOLU Clinical Criteria
| LU Code | Auth. Period | Clinical Criteria |
|---|---|---|
| 517 | 1 year | Confirmed chronic Hepatitis B infection in persons with - HBV DNA greater than or equal to 1000 IU/mL AND - ALT levels greater than ULN OR - Evidence of fibrosis OR - Documented evidence of cirrhosis |
| 518 | 1 year | For patients with chronic Hepatitis B infection who have a contraindication, intolerance or inadequate response to one or more of the following: lamivudine, entecavir, adefovir or telbivudine. |
| 519 | 1 year | Patient is pregnant (2nd trimester or later) with HBV DNA greater than 1,000,000 IU/mL. |
| 520 | 1 year | Patients with chronic Hepatitis B infection currently receiving treatment with tenofovir and requires treatment continuation. |
| 521 | 1 year | Patients with chronic Hepatitis B infection who are scheduled to undergo chemotherapy or significant immunosuppressive treatment. |
Requirements